Markers of stroke and stroke severity
A technology for stroke, ischemic stroke, applied in the field of markers of stroke and stroke severity, which can solve the problem of unavailable imaging technology
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0217] Example 1 - Comparison of gene expression patterns of biomarkers between ischemic stroke patients, transient ischemic attack patients and pseudo-stroke patients using PCR.
[0218] Peripheral blood samples from four groups of patients (i.e., 8 patients with ischemic stroke, 4 patients with transient ischemic attack (TIA), 7 patients with sham stroke, and 19 control patients) were collected within 24 hours of symptom onset. Blood plasma samples were collected into PAXgene blood RNA tubes (Qiagen). Whole blood RNA was extracted and purified using the PAXgene Blood RNA Kit (Qiagen).
[0219] PCR was performed to measure the gene expression of ARG1, CA4, CCR7, CSPG2, IQGAP1, LY96, MMP9, ORM1 and s100a12 relative to the control group. The expression levels of ARG1 (p=0.038), CCR7 (p=0.003), LY96 (p=0.018), CSPG2 (p=0.05) were significantly different among the ischemic stroke group, TIA group and sham stroke group ( figure 1).
[0220] PCR was also performed to measure t...
Embodiment 2
[0225] Example 2 - Comparison of gene expression patterns of biomarkers between ischemic stroke patients and metabolic disease controls using PCR.
[0226] Peripheral plasma samples from 22 ischemic stroke patients and 19 metabolic disease control patients were collected into PAXgene blood RNA tubes (Qiagen) within 24 hours of symptom onset. Whole blood RNA was extracted and purified using the PAXgene Blood RNA Kit.
[0227] PCR was performed to measure gene expression of ARG, MMP9, s100a12 and CCR7. ARG1 (p=0.003), MMP9 (p=0.001), s100a12 (p=0.018) and CCR7 (p=0.000) expression levels were significantly different between stroke and metabolic disease controls ( Figures 6A-6D ).
[0228] The interaction between ARG1, MMP9 and s100a12 was significantly different between the ischemic stroke group and the metabolic disease control group (p=0.009) ( Figure 7 ). This interaction is the expression pattern of all variables of interest. Pattern recognition and machine learning...
Embodiment 3
[0229] Example 3 -Comparison of protein expression patterns of biomarkers between ischemic stroke patients, transient ischemic attack patients and pseudo-stroke patients using ELISA.
[0230] Whole blood samples from three groups of patients (ie, 4 ischemic stroke patients, 2 TIA patients and 2 pseudo-stroke patients) were collected into EDTA tubes (Becton Dickinson). Plasma was removed by centrifugation.
[0231] Protein expression of ARG1, CA4, CCR7, CSPG2, IQGAP1, LY96, MMP9, RAGE and ORM1 was measured using commercially available ELISA kits. The protein expression levels of ARG1 (p=0.048) and LY96 (p=0.056) were significantly different among the ischemic stroke group, TIA group and sham stroke group ( Figures 8A-8B ).
[0232] The interactions between LY96 and ARG (p=0.07) and LY96 and CCR7 (p=0.09) were significantly different among the three groups ( Figures 9A-9B ), indicating different protein expression patterns between groups. This interaction is the expressi...
PUM
| Property | Measurement | Unit |
|---|---|---|
| volume | aaaaa | aaaaa |
| Sensitivity | aaaaa | aaaaa |
| Sensitivity | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More